|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MECR |
Gene summary for MECR |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MECR | Gene ID | 51102 |
| Gene name | mitochondrial trans-2-enoyl-CoA reductase | |
| Gene Alias | CGI-63 | |
| Cytomap | 1p35.3 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q9BV79 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51102 | MECR | LZE7T | Human | Esophagus | ESCC | 1.11e-02 | 2.19e-01 | 0.0667 |
| 51102 | MECR | LZE8T | Human | Esophagus | ESCC | 9.50e-03 | 9.13e-02 | 0.067 |
| 51102 | MECR | LZE20T | Human | Esophagus | ESCC | 4.25e-02 | 1.76e-01 | 0.0662 |
| 51102 | MECR | LZE22T | Human | Esophagus | ESCC | 9.52e-04 | 2.71e-01 | 0.068 |
| 51102 | MECR | LZE24T | Human | Esophagus | ESCC | 2.03e-08 | 2.40e-01 | 0.0596 |
| 51102 | MECR | LZE6T | Human | Esophagus | ESCC | 1.00e-02 | 1.24e-01 | 0.0845 |
| 51102 | MECR | P2T-E | Human | Esophagus | ESCC | 2.01e-20 | 3.33e-01 | 0.1177 |
| 51102 | MECR | P4T-E | Human | Esophagus | ESCC | 8.10e-08 | 2.02e-01 | 0.1323 |
| 51102 | MECR | P5T-E | Human | Esophagus | ESCC | 3.35e-13 | 2.26e-01 | 0.1327 |
| 51102 | MECR | P8T-E | Human | Esophagus | ESCC | 1.73e-12 | 2.62e-01 | 0.0889 |
| 51102 | MECR | P9T-E | Human | Esophagus | ESCC | 2.40e-02 | 7.77e-02 | 0.1131 |
| 51102 | MECR | P10T-E | Human | Esophagus | ESCC | 1.59e-15 | 2.65e-01 | 0.116 |
| 51102 | MECR | P11T-E | Human | Esophagus | ESCC | 1.66e-07 | 3.38e-01 | 0.1426 |
| 51102 | MECR | P12T-E | Human | Esophagus | ESCC | 1.49e-08 | 1.93e-01 | 0.1122 |
| 51102 | MECR | P15T-E | Human | Esophagus | ESCC | 2.59e-12 | 3.21e-01 | 0.1149 |
| 51102 | MECR | P16T-E | Human | Esophagus | ESCC | 1.25e-10 | 1.72e-01 | 0.1153 |
| 51102 | MECR | P17T-E | Human | Esophagus | ESCC | 2.43e-08 | 4.31e-01 | 0.1278 |
| 51102 | MECR | P19T-E | Human | Esophagus | ESCC | 4.87e-07 | 6.09e-01 | 0.1662 |
| 51102 | MECR | P20T-E | Human | Esophagus | ESCC | 5.88e-10 | 2.43e-01 | 0.1124 |
| 51102 | MECR | P21T-E | Human | Esophagus | ESCC | 2.07e-26 | 5.23e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
| GO:007233021 | Liver | HCC | monocarboxylic acid biosynthetic process | 129/7958 | 214/18723 | 1.08e-07 | 2.09e-06 | 129 |
| GO:000663321 | Liver | HCC | fatty acid biosynthetic process | 96/7958 | 163/18723 | 1.71e-05 | 1.85e-04 | 96 |
| GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
| GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
| GO:00066317 | Oral cavity | OSCC | fatty acid metabolic process | 186/7305 | 390/18723 | 2.65e-04 | 1.69e-03 | 186 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
| hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa000622 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
| hsa00061 | Liver | HCC | Fatty acid biosynthesis | 14/4020 | 18/8465 | 8.82e-03 | 2.36e-02 | 1.32e-02 | 14 |
| hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa0006211 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
| hsa000611 | Liver | HCC | Fatty acid biosynthesis | 14/4020 | 18/8465 | 8.82e-03 | 2.36e-02 | 1.32e-02 | 14 |
| hsa012128 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
| hsa0121213 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MECR | insertion | Frame_Shift_Ins | novel | c.225_226insGAAGGCAGCCCAGATACCCAGGTTCCAGCTCCAACTCTGC | p.Lys76GlufsTer24 | p.K76Efs*24 | Q9BV79 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| MECR | SNV | Missense_Mutation | novel | c.524T>C | p.Leu175Ser | p.L175S | Q9BV79 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MECR | SNV | Missense_Mutation | rs770619410 | c.470C>T | p.Pro157Leu | p.P157L | Q9BV79 | protein_coding | deleterious(0) | benign(0.337) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MECR | SNV | Missense_Mutation | novel | c.662N>C | p.Ile221Thr | p.I221T | Q9BV79 | protein_coding | deleterious(0) | benign(0.181) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| MECR | SNV | Missense_Mutation | rs143281690 | c.736N>A | p.Glu246Lys | p.E246K | Q9BV79 | protein_coding | tolerated(0.07) | benign(0.07) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MECR | SNV | Missense_Mutation | novel | c.903T>G | p.Ile301Met | p.I301M | Q9BV79 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| MECR | SNV | Missense_Mutation | novel | c.920T>A | p.Leu307His | p.L307H | Q9BV79 | protein_coding | deleterious(0) | possibly_damaging(0.694) | TCGA-2E-A9G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | CR |
| MECR | SNV | Missense_Mutation | rs759114736 | c.458N>T | p.Pro153Leu | p.P153L | Q9BV79 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MECR | SNV | Missense_Mutation | rs746554300 | c.353N>G | p.Asn118Ser | p.N118S | Q9BV79 | protein_coding | tolerated(0.69) | benign(0) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MECR | SNV | Missense_Mutation | rs750365471 | c.236C>T | p.Ala79Val | p.A79V | Q9BV79 | protein_coding | tolerated(0.07) | possibly_damaging(0.87) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |